Logos Capital
Logos Capital is a hedge fund manager based in San Francisco, founded in 2019, specializing in fundamental biotechnology investments. The firm combines in-house data analytics with scientific and clinical expertise to rigorously evaluate potential therapies and treatment platforms. It uses fundamental and sector-focused equity strategies and applies statistical modeling of clinical data to strengthen diligence and identify compelling opportunities with the aim of delivering uncorrelated returns. By integrating medical, scientific, and statistical perspectives, Logos Capital seeks to deepen its conviction in investment ideas and maintain disciplined risk management.
Top Stages
https://crunchbase.com/organization/***
https://linkedin.com/company/***
Past deals in Boston, MA
Elektrofi
Series C in 2024
Founded in Boston in 2016, Elektrofi is a preclinical-stage company focused on revolutionizing drug delivery. Its proprietary formulation system can efficiently process a wide range of therapeutic molecules, including large and complex proteins like monoclonal antibodies.
Scorpion Therapeutics
Series C in 2024
Founded in 2020 and headquartered in Boston, Massachusetts, Scorpion Therapeutics is a clinical-stage biotechnology company specializing in precision oncology. It develops targeted small-molecule drugs to treat cancer by focusing on three areas: therapies against known oncogenes, agents for currently undruggable targets, and drugs for new targets.
Elektrofi
Series B in 2022
Founded in Boston in 2016, Elektrofi is a preclinical-stage company focused on revolutionizing drug delivery. Its proprietary formulation system can efficiently process a wide range of therapeutic molecules, including large and complex proteins like monoclonal antibodies.
Scorpion Therapeutics
Series B in 2021
Founded in 2020 and headquartered in Boston, Massachusetts, Scorpion Therapeutics is a clinical-stage biotechnology company specializing in precision oncology. It develops targeted small-molecule drugs to treat cancer by focusing on three areas: therapies against known oncogenes, agents for currently undruggable targets, and drugs for new targets.
Ikena Oncology
Series B in 2021
Ikena Oncology, Inc. is a biotechnology company focused on discovering and developing biomarker-driven therapies for cancer treatment. It specializes in precision oncology by targeting pathways essential for cancer growth and therapeutic resistance, particularly within the Hippo and RAS signaling networks. The company's portfolio includes several preclinical and discovery-stage programs, such as IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; and IK-412, a kynurenine-degrading enzyme. Additionally, Ikena is developing IK-930, an oral small-molecule inhibitor of the TEAD transcription factor involved in the Hippo pathway. Ikena Oncology, originally founded as Kyn Therapeutics in 2016, rebranded in December 2019 and is headquartered in Boston, Massachusetts. The company aims to address significant medical needs in oncology through innovative drug development.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.